MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, VVOS had -$1,315K decrease in cash & cash equivalents over the period. -$4,078K in free cash flow.

Cash Flow Overview

Change in Cash
-$1,315K
Free Cash flow
-$4,078K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss
-5,399 -8,877
Stock-based compensation expense
55 559
Paid-in-kind interest expense on promissory note
100 -
Depreciation and amortization
384 483
Fair value of common stock issued for services
-0
Accounts receivable
501 269
Non-cash interest expense on promissory note
-100
Operating lease liabilities, net
-7 -67
Prepaid expenses and other current assets
-130 -98
Deposits
16 -64
Accounts payable
340 608
Accrued expenses
442 -127
Other liabilities
358 646
Fair value of warrants issued for services
-0
Contract liability
53 -508
Net cash used in operating activities
-4,161 -7,290
Payment for acquisition, net of excess cash of 865
0 5,135
Acquisitions of property and equipment
-83 893
Net cash used in investing activities
83 -6,028
Proceeds from issuance of debt
-417 9,642
Proceeds from issuance of common stock
2,428 347
Proceeds from issuance of warrants
1,699 -
Proceeds from issuance of pre-funded warrants
609 -
Proceeds from exercise of warrants
-833 1,699
Payments for issuance costs
0 837
Reduction of finance lease liability
17 -
Proceeds from issuance of pre-funded warrants
-609
Reduction of debt liability
97 -
Net cash provided by financing activities
2,763 11,460
Net increase (decrease) in cash and cash equivalents
-1,315 -1,858
Cash and cash equivalents at beginning of period
6,260 -
Cash and cash equivalents at end of period
3,087 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Vivos Therapeutics, Inc. (VVOS)

Vivos Therapeutics, Inc. (VVOS)